A randomized controlled trial has put two clinic-based “minoxidil booster” procedures head to head in women with androgenetic alopecia—and fractional microneedling radiofrequency (FMRF) came out ahead.
Researchers at Cairo University compared four monthly sessions of fractional radiofrequency microneedling or fractional CO₂ laser, each used on one side of the scalp while all participants continued 5% topical minoxidil. The untreated comparison side received minoxidil alone. All three approaches improved trichoscopic hair counts and density, but the FMRF-plus-minoxidil side produced a significantly greater increase than either CO₂ laser plus minoxidil or minoxidil alone.
This is encouraging human evidence for a treatment-resistant group, but it is not a green light for home radiofrequency devices. The study included only 30 women, followed them for a short period and tested clinician-delivered procedures under controlled settings.
What Is It and How Does It Work?
Fractional microneedling radiofrequency uses insulated or semi-insulated needles to place controlled thermal injury at selected depths in the scalp. Unlike a fractional CO₂ laser, which creates ablative microcolumns from the surface downward, FMRF can concentrate heat in the dermis while limiting damage to the epidermis.
- Controlled wound-healing signal: Microscopic injury activates a repair response involving fibroblasts, extracellular-matrix remodelling and growth-factor signalling. These changes may improve the perifollicular environment, but the exact hair-growth pathway was not directly measured in this trial.
- Potential follicular stimulation: Radiofrequency energy can deliver thermal stimulation around the upper and mid dermis, where follicular structures and signalling cells reside. It is plausible that this nudges miniaturising follicles toward a more growth-supportive state; it is not yet proven that FMRF independently switches follicles into anagen.
- Minoxidil remains the foundation: Every participant used 5% minoxidil. The study therefore tested FMRF as an adjunct—not as a replacement for evidence-based medical treatment.
- Why it may beat fractional CO₂: FMRF can target deeper tissue with less surface ablation. The trial’s result suggests that depth-controlled dermal heating may be more useful than surface-down laser microchannels in this setting, but it did not isolate which physical mechanism caused the difference.
The Science: What the Randomized Trial Actually Found
The study enrolled 30 women with female androgenetic alopecia and used a split-scalp design. Participants were randomized into two procedure groups. In one group, fractional CO₂ laser was applied to one randomly selected side of the scalp; in the other, FMRF was applied to one randomly selected side. All women used topical minoxidil 5%, allowing each participant’s minoxidil-only side to act as an internal comparison.
- All approaches improved: Trichoscopic hair counts and density increased significantly with minoxidil alone, minoxidil plus fractional CO₂, and minoxidil plus FMRF.
- FMRF produced the strongest signal: The FMRF-plus-minoxidil side achieved a significantly greater increase in trichoscopic hair count and density than either the CO₂-plus-minoxidil side or minoxidil alone.
- CO₂ was not the winner: Although fractional CO₂ plus minoxidil improved from baseline, the abstract does not establish that it delivered the same advantage over minoxidil that FMRF did.
- Tolerability favoured FMRF: The authors concluded that the radiofrequency combination may offer higher efficacy and tolerability than the other tested approaches.
The paper was published in Dermatologic Surgery and is indexed as PMID 40919794 (DOI: 10.1097/DSS.0000000000004839).
What This Study Does Not Prove
- Thirty participants is a pilot-sized sample: Small studies can exaggerate treatment effects and are not large enough to define uncommon adverse events.
- No long-term durability answer: The trial does not show how much of the added density remains months after procedures stop.
- No procedure-only arm: Because everyone used 5% minoxidil, the study cannot tell us how well FMRF works by itself.
- No DIY equivalence: Consumer radiofrequency or microneedling gadgets do not reproduce medical device depth, energy, sterility or treatment geometry.
- Female-pattern hair loss is not one diagnosis: Diffuse shedding, thyroid disease, iron deficiency, scarring alopecia and medication-related loss can resemble it. A procedure will not correct an unrecognised underlying cause.
When Will It Be Available?
- Current stage: FMRF is already available through dermatology and aesthetic clinics, but its use for androgenetic alopecia is an off-label procedural strategy rather than a universally standardised hair-loss protocol.
- What is still missing: Larger multicentre trials need to define the best needle depth, energy, number of passes, treatment interval, maintenance schedule and long-term safety.
- Practical timeline: This is not a drug waiting for approval, but evidence-based treatment parameters may take years to settle. Availability today does not mean every clinic protocol is equally validated.
How You Can Benefit From This Research Now
- Confirm the diagnosis first: Ask a dermatologist to distinguish female-pattern hair loss from telogen effluvium, traction, inflammatory scalp disease and scarring alopecia before paying for a device-based course.
- Use it as an adjunct, not a substitute: The strongest result was FMRF combined with 5% minoxidil. Do not stop prescribed therapy because a clinic offers a procedure.
- Ask for the exact protocol: Request the device name, needle depth, energy settings, number of passes, session interval, infection-control method and clinician experience. “Radiofrequency microneedling” is a broad category, not a single treatment.
- Track objectively: Take same-angle, same-light photographs and, ideally, baseline trichoscopy. Reassess after a full hair-cycle interval rather than judging shedding or texture week by week.
- Know when to pause: Active scalp infection, open wounds, uncontrolled inflammatory scalp disease, bleeding-risk medication or a tendency to abnormal scarring require medical review before treatment. Pregnancy and breastfeeding also warrant individual clinician guidance.
Action: If minoxidil has produced only partial improvement after consistent use, bring this trial to a qualified dermatologist and ask whether a medically delivered FMRF adjunct is reasonable for your diagnosis, scalp condition and risk profile.
Source: Hilal RF et al., Dermatologic Surgery — PMID 40919794; DOI 10.1097/DSS.0000000000004839.